1. Jouanneau, J., Moens, G., Bourgeois, Y., Poupon, M. F. & Thiery, J. P. A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc. Natl Acad. Sci. USA 91, 286–290 (1994).

2. Axelrod, R., Axelrod, D. & Pienta, K. J. Evolution of cooperation among tumor cells. Proc. Natl Acad. Sci. USA 103, 13474–13479 (2006).

3. Archetti, M., Ferraro, D. A. & Christofori, G. Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc. Natl Acad. Sci. USA 112, 1833–1838 (2015).

4. Cleary, A. S., Leonard, T. L., Gestl, S. A. & Gunther, E. J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508, 113–117 (2014).

5. Tabassum, D. P. & Polyak, K. Tumorigenesis: it takes a village. Nat. Rev. Cancer 8, 473–483 (2015).

6. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239–252 (2009).

7. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).

8. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012).

9. MacDougall-Shackleton, S. A. The levels of analysis revisited. Phil. Trans. R. Soc. B 366, 2076–2085 (2011).

10. Mayr, E. Cause and effect in biology. Science 134, 1501–1506 (1961).

11. Tinbergen, N. On aims and methods in ethology. Z. Tierpsychol. 20, 410–433 (1963).

12. Maynard Smith, J. Group selection and kin selection. Nature 201, 1145–1147 (1964).

13. Williams, G. C. Adaptation and Natural Selection: A Critique of Some Current Evolutionary Thought (Princeton Univ. Press, 1972).

14. Dawkins, R. The Selfish Gene (Oxford University Press, 1976).

15. Hardin, G. The tragedy of the commons. Science 162, 1243–1248 (1968).

16. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).

17. Cairns, J. Mutation, selection and the natural history of cancer. Nature 255, 197–200 (1975).

18. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).

19. Axelrod, R. & Hamilton, W. D. The evolution of cooperation. Science 211, 1390–1396 (1981).

20. Mesterton-Gibbons, M. & Adams, E. S. The economics of animal cooperation. Science 298, 2146–2147 (2002).

21. Nowak, M. A. Five rules for the evolution of cooperation. Science 314, 1560–1563 (2006).

22. West, S. A., Griffin, A. S. & Gardner, A. Evolutionary explanations for cooperation. Curr. Biol. 17, R661–R672 (2007).

23. Gintis, H. & Bowles, S. A Cooperative Species: Human Reciprocity and Its Evolution (Princeton Univ. Press, 2011).

24. Tomasello, M. Why We Cooperate (MIT Press, 2009).

25. Axelrod, R. The Evolution of Cooperation (Basic Books, 1984).

26. Rasmusen, E. Games and Information: An Introduction To Game Theory (Wiley-Blackwell, 2006).

27. Osborne, M. An Introduction to Game Theory (Oxford Univ. Press, 2003).

28. Fudenberg, D. & Tirole, J. Game Theory (MIT Press, 1991).

29. Myerson, R. Game Theory: Analysis of Conflict (Harvard Univ. Press, 1997).

30. Maynard Smith, J. Evolution and the Theory of Games (Cambridge Univ. Press, 1982).

31. McElreath, R. & Boyd, R. Mathematical Models of Social Evolution: A Guide For The Perplexed (Univ. of Chicago Press, 2007).

32. Dugatkin, L. & Reeve, H. Game Theory and Animal Behaviour (Oxford Univ. Press, 1998).

33. Hofbauer, J. & Sigmund, K. Evolutionary Games and Population Dynamics (Cambridge Univ. Press, 1998).

34. Tucker, A. in Reading in Games and Information (ed. Rasmusen, E.) 7–8 (Blackwell Publishers, 2001).

35. Tomlinson, I. P. Game-theory models of interactions between tumour cells. Eur. J. Cancer 33, 1495–1500 (1997).

36. Tomlinson, I. P. & Bodmer, W. F. Modelling consequences of interactions between tumour cells. Br. J. Cancer 75, 157–160 (1997).

37. Rapoport, A. & Chammah, A. M. The game of chicken. Am. Behav. Sci. 10, 10–28 (1966).

38. Sugden, R. The Economics of Rights, Cooperation and Welfare (B. Blackwell, Oxford, 1986).

39. Maynard Smith, J. & Price, G. R. The logic of animal conflict. Nature 246, 15–18 (1973).

40. Bach, L. A., Bentzen, S., Alsner, J. & Christiansen, F. B. An evolutionary-game model of tumour cell interactions, possible relevance to gene therapy. Eur. J. Cancer 37, 2116–2120 (2001).

41. Bach, L. A., Sumpter, D. J. T., Alsner, J. & Loeschke, V. Spatial evolutionary games of interaction among generic cancer cells. J. Theor. Med. 5, 47–58 (2003).

42. Basanta, D., Hatzikirou, H. & Deutsch, A. Studying the emergence of invasiveness in tumours using game theory. Eur. Phys. J. 63, 393–397 (2008).

43. Basanta, D., Simon, M., Hatzikirou, H. & Deutsch, A. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell Prolif. 41, 980–987 (2008).

44. Basanta, D., Scott, J. G., Rockne, R., Swanson, K. R. & Anderson, A. R. The role of IDH1 mutated tumour cells in secondary glioblastomas, an evolutionary game theoretical view. Phys. Biol. 8, 015016 (2011).

45. Basanta, D. et al. Investigating prostate cancer tumour-stroma interactions, clinical and biological insights from an evolutionary game. Br. J. Cancer 106, 174–181 (2012).

46. Dingli, D., Chalub, F. A., Santos, F. C. & Pacheco, J. Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br. J. Cancer 101, 1130–1136 (2009).

47. Gerstung, M., Nakhoul, H. & Beerenwinkel, N. Evolutionary games with affine fitness functions, applications to cancer. Dyn. Games Appl. 1, 370–385 (2011).

48. You, L. et al. Spatial versus non-spatial eco-evolutionary dynamics in a tumor growth model. J. Theor. Biol. 435, 78–97 (2017).

49. Zhang, J. S., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).

50. Archetti, M. Dynamics of growth factor production in monolayers of cancer cells. Evol. Appl. 6, 1146–1159 (2013).

51. Archetti, M. Cooperation among cancer cells as public goods games on Voronoi networks. J. Theor. Biol. 396, 191–203 (2016).

52. Archetti, M. Stable heterogeneity for the production of diffusible factors in cell populations. PLOS ONE 9, e108526 (2014).

53. Archetti, M. Evolutionary game theory of growth factor production, implications for tumor heterogeneity and resistance to therapies. Br. J. Cancer 109, 1056–1062 (2013).

54. Yang, J., Zhao, T. J., Yuan, C. Q., Xie, J. H. & Hao, F. F. A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression. J. Theor. Biol. 404, 66–72 (2016).

55. Kianercy, A., Veltri, R. & Pienta, K. J. Critical transitions in a game theoretic model of tumour metabolism. Interface Focus 4, 20140014 (2014).

56. Kaznatcheev, A., Vander Velde, R., Scott, J. G. & Basanta, D. Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature. Br. J. Cancer. 116, 785–792 (2017).

57. Archetti, M. Evolutionary dynamics of the Warburg effect, glycolysis as a collective action problem among cancer cells. J. Theor. Biol. 341, 1–8 (2014).

58. Archetti, M. Heterogeneity and proliferation of invasive cancer subclones in game theory models of the Warburg effect. Cell Prolif. 482, 259–269 (2015).

59. Cirri, P. & Chiarugi, P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 1, 482–497 (2011).

60. Sartakhti, J. S., Manshaei, M. H. & Sadeghi, M. MMP-TIMP interactions in cancer invasion: an evolutionary game-theoretical framework. J. Theor. Biol. 412, 17–26 (2017).

61. Sartakhti, J. S., Manshaei, M. H. & Archetti, M. Game theory of tumor–stroma interactions in multiple myeloma: effect of nonlinear benefits. Games 9, 32 (2018).

62. Sartakhti, J. S., Manshaei, M. H., Bateni, S. & Archetti, M. Evolutionary dynamics of tumor-stroma interactions in multiple myeloma. PLOS ONE 11, e0168856 (2016).

63. Kaiser Wilhelm Institut für Biologie. Über Den Stoffwechsel Der Tumoren: The Metabolism of Tumours (ed. Warburg, O.) (Constable, London, 1930).

64. Nakajima, E. C. & Van Houten, B. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol. Carcinog. 52, 329–337 (2013).

65. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 11, 85–95 (2011).

66. Gatenby, R. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004).

67. Pavlides, S. et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984–4001 (2009).

68. Bonuccelli, G. et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9, 3506–3514 (2010).

69. Xing, Y., Zhao, S., Zhou, B. P. & Mi, J. Metabolic reprogramming of the tumour microenvironment. FEBS J. 282, 3892–3898 (2015).

70. Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).

71. Loo, J. M. et al. Extracellular metabolic energetics can promote cancer progression. Cell 160, 393–406 (2015).

72. Webber, J., Yeung, V. & Clayton, A. Extracellular vesicles as modulators of the cancer microenvironment. Semin. Cell Dev. Biol. 40, 27–34 (2015).

73. Fong, M. Y. et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015).

74. Archetti, M. et al. Economic game theory for mutualism and cooperation. Ecol. Lett. 14, 1300–1312 (2011).

75. Archetti, M. & Scheuring, I. Review: game theory of public goods in one-shot social dilemmas without assortment. J. Theor. Biol. 299, 9–20 (2012).

76. Aktipis, A. Principles of cooperation across systems: from human sharing to multicellularity and cancer. Evol. Appl. 9, 17–36 (2016).

77. Archetti, M. The volunteer’s dilemma and the optimal size of a social group. J. Theor. Biol. 261, 475–480 (2009).

78. Archetti, M. Cooperation as a volunteer’s dilemma and the strategy of conflict in public goods games. J. Evol. Biol. 22, 2192–2200 (2009).

79. Moreno, E. Is cell competition relevant to cancer? Nat. Rev. Cancer 8, 141–147 (2008).

80. Merino, M. M., Levayer, R. & Moreno, E. Survival of the fittest: essential roles of cell competition in development, aging, and cancer. Trends Cell Biol. 26, 776–788 (2016).

81. Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 549–559 (2015).

82. Shubik, M. Readings in Game Theory and Political Behavior 43–46 (Doubleday, 1954).

83. Archetti, M. Survival of the weakest in N-person duels and the maintenance of variation under constant selection. Evolution 66, 637–650 (2012).

84. Fox, J. & Guyer, M. Public choice and cooperation in N-person prisoner’s dilemma. J. Conflict Resolut. 22, 469–481 (1978).

85. Hamburger, H. N-person prisoner’s dilemma. J. Math. Sociol. 3, 27–48 (1973).

86. Grafen, A. & Archetti, M. Natural selection of altruism in inelastic homogeneous viscous populations. J. Theor. Biol. 252, 694–710 (2008).

87. Cornish-Bowden, A. Fundamentals of Enzyme Kinetics (Wiley, 2012).

88. Archetti, M. & Scheuring, I. Coexistence of cooperation and defection in public goods games. Evolution 65, 1140–1148 (2011).

89. Archetti, M. How to analyze models of nonlinear public goods. Games 9, 17 (2018).

90. de Groot, A. E., Roy, S., Brown, J. S., Pienta, K. J. & Amend, S. R. Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis. Mol. Cancer Res. 15, 361–370 (2017).

91. Nagy, J. D. Competition and natural selection in a mathematical model of cancer. Bull. Math. Biol. 66, 663–687 (2004).

92. Archetti, M. & Scheuring, I. Trading public goods stabilizes interspecific mutualism. J. Theor. Biol. 318, 58–67 (2013).

93. Valkenburg, K. C., de Groot, A. E. & Pienta, K. J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15, 366–381 (2018).

94. Aktipis, C. A., Kwan, V. S. Y., Johnson, K. A., Neuberg, S. L. & Maley, C. C. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLOS ONE 6, e26100 (2011).

95. Myerson, R. B. in The New Palgrave Dictionary of Economics 2nd edn (eds Durlauf, S. N. & Blume, L. E.) 533–542 (Palgrave Macmillan UK, 2008).

96. Gillies, R. J., Verduzco, D. & Gatenby, R. A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer. 12, 487–493 (2012).

97. Gatenby, R. A. A change of strategy in the war on cancer. Nature 459, 508–509 (2009).

98. Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894–4903 (2009).

99. Enriquez-Navas, P. M. et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl Med. 8, 327ra24 (2016).

100. Read, A. F., Day, T. & Huijben, S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl Acad. Sci. USA 108, 10871–10877 (2011).

101. Day, T., Huijben, V. & Read, A. F. Is selection relevant in the evolutionary emergence of drug resistance? Trends Microbiol. 23, 126–133 (2015).

102. Day, T. & Read, A. F. Does high-dose antimicrobial chemotherapy prevent the evolution of resistance? PLOS Comput. Biol. 12, e1004689 (2016).

103. Martin, R., Fisher, M., Minchin, R. & Teo, K. Low-intensity combination chemotherapy maximizes host survival time for tumors containing drug-resistant cells. Math. Biosci. 110, 221–152 (1992).

104. Hansen, E., Woods, R. J. & Read, A. F. How to use a chemotherapeutic agent when resistance to it threatens the patient. PLOS Biol. 15, e2001110 (2017).

105. Merlo, L. M. F., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924–935 (2006).

106. Silva, A. S. & Gatenby, R. A. A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol. Direct. 5, 25 (2010).

107. Gatenby, R. A., Gillies, R. J. & Brown, J. S. The evolutionary dynamics of cancer prevention. Nat. Rev. Cancer 10, 526–527 (2010).

108. Basanta, D., Gatenby, R. A. & Anderson, A. R. An exploiting evolution to treat drug resistance: combination therapy and the double bind. Mol. Pharm. 9, 914–921 (2012).

109. Aktipis, C. A. & Nesse, R. M. Evolutionary foundations for cancer biology. Evol. Appl. 6, 144–159 (2013).

110. André, J. B. & Godelle, B. Multicellular organization in bacteria as a target for drug therapy. Ecol. Lett. 8, 800–810 (2005).

111. Pepper, J. W. Drugs that target pathogen public goods are robust against evolved drug resistance. Evol. Appl. 5, 757–761 (2012).

112. Jansen, G., Gatenby, R. & Aktipis, C. A. Opinion: control versus eradication: applying infectious disease treatment strategies to cancer. Proc. Natl Acad. Sci. USA 112, 937–938 (2015).

113. Archetti, M. Evolutionarily stable anti-cancer therapies by autologous cell defection. Evol. Med. Public Health 1, 161–172 (2013).

114. Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M. & Pienta, K. J. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J. Clin. 57, 225–241 (2007).